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Pollinex Quattro® and SDT in grass pollen-induced AR in Spain. Findings are con-
firmed by extensive sensitivity analyses.
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Objectives: Endobronchial valve therapy (EBV) is an innovative treatment that 
has been shown to be safe and effective in selected subgroups of patients with 
severe emphysema. The objective of our study was to assess the cost-effectiveness 
of valve treatment in the German health care system when compared to medical 
management. MethOds: Clinical data from a subset of the Endobronchial Valve 
for Emphysema Palliation Trial (VENT) provided information about clinical events, 
health-related quality of life, and disease staging through 12 months. This informa-
tion was subsequently used as input to a previously published Markov model to 
project longer-term disease progression, mortality, and health resource utilization. 
From this combined analysis, we computed the 5-year and 10-year incremental 
cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY). Costs 
and effects were discounted at 3% per year. Results: EBV therapy led to clini-
cally meaningful disease restaging at 12 months (37.8% of cohort improved staging, 
compared to 0% in control). Over 5 years, EBV was projected to increase survival 
from 66.4% to 70.7%, and to add 0.22 QALYs. Costs were estimated to increase by € 
10,299, resulting in an ICER of € 46,322/QALY. Over 10 years, 0.41 QALYs were gained 
at additional cost of € 10,425, yielding an ICER of € 25,142/QALY. cOnclusiOns: Our 
model-based analysis suggests that EBV leads to clinically meaningful changes in 
disease staging and progression when compared to medical management, with 
resulting gains in unadjusted and quality-adjusted life expectancy. Relative to the 
acknowledged willingness-to-pay threshold of € 50,000/QALY, our results indicate 
EBV is a cost-effective therapy in the German health care system.
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Objectives: Allergic rhinitis (AR) affects 10-20% of the US population, with treat-
ment costs exceeding $6 billion annually and has been shown to have a substantial 
impact on productivity. In the U. S. AR is estimated to result in 3.5 million lost work 
days and 2 million lost school days annually. AZ/FP is an intranasal formulation 
of azelastine hydrochloride and fluticasone propionate in an advanced delivery 
system indicated for the relief of symptoms of seasonal AR (SAR). Patients treated 
with AZ/FP experience significantly greater and faster symptom relief in compari-
son to first-line therapy in trials, and thus have the potential to positively impact 
workplace productivity. We use an economic model to calculate the economic effects 
on workplace productivity associated with moving AZ/FP from third-tier to second-
tier pricing and reimbursement. MethOds: Population is SAR sufferers seeking 
treatment. AZ/FP is assumed to gain market share annually with second-tier pric-
ing. Time horizon is one year and five years. Four step approach: (1) estimate total 
number of AR-related symptomatic days; (2) calculate total number of AR-related 
episodes per year multiplied by number of days per episode; (3) estimate number of 
these days that occur during a standard 5-day work week; & (4) Estimate proportion 
of AR symptomatic days resulting in absenteeism or presenteeism. Results: For 
a typical health plan, the estimate of expected number of absenteeism and pres-
enteeism days per AZ/FP patient associated with moving AZ/FP from Tier 3 to Tier 
2 resulted in a reduction of 4,729 AR-symptomatic days annually. Total workplace 
cost savings ranged from $168,838 (Year 1) to $190,937 (Year 5), with the proportional 
effects on absenteeism and presenteeism being roughly equal. cOnclusiOns: AZ/
FP offers an appropriate means of adhering to AR practice guidelines and improv-
ing outcomes. This workplace productivity model shows that the added benefits to 
employers could be substantial.
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Objectives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta 
agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was devel-
oped to assess the potential societal cost benefits of improved inhalation technique 
with DuoResp® Spiromax® compared with Symbicort® Turbuhaler®– a DPI delivering 
the same FDC – in the management of adult patients with persistent asthma and 
chronic obstructive pulmonary disease (COPD) in Sweden. MethOds: The eligible 
adult patient population was based on statistics from the National Board of Health 
and Welfare in Sweden. Societal costs (lost productivity) were based on the annual 
number of work-days lost for asthma and COPD patients in Sweden and the United 
Kingdom (UK), respectively, and the average daily cost of sick leave in Sweden. 
Frequency of poor inhalation technique with Symbicort® Turbuhaler® and the sub-
sequent increased risk of unscheduled health care events were taken from a large 
(n= 1,664) cross-sectional, Italian observational study. The estimated reduction in the 
proportion of patients with poor inhalation technique with DuoResp® Spiromax® 
Objectives: Severe asthma is a major cause of morbidity and mortality around 
the world, associated with a heavy societal burden. The aim of this study was to 
evaluate the economic value of omalizumab in the treatment of adult patients 
with severe allergic asthma in Greece, from a societal perspective, based on data 
collected from a clinical trial (INNOVATE) and real-world evidence (RWE) from a 
prospective observational study conducted in Greece. MethOds: A Markov cohort 
model was developed in Microsoft Excel to compare the costs and outcomes of 
omalizumab plus standard therapy (ST, primarily comprised ICS, LABA and SABA) 
versus ST alone. The time horizon was that of a lifetime. Both direct and indirect 
costs were incorporated. Health outcomes considered were Quality Adjusted Life 
Years (QALYs). Costs and QALYs were discounted annually at 3.5%. Unit costs 
were taken from publically available sources. Productivity losses were calculated 
based on published data, while utility values were taken from the INNOVATE 
study. Deterministic and probabilistic sensitivity analyses were undertaken to 
test the robustness of the model results. Results: The addition of omalizumab 
to ST led to an incremental cost per QALY gained of € 27,888 based on INNOVATE 
trial and € 27,255 based on the RWE. The model appeared to be most sensitive to 
changes in the time horizon and the age of retirement. Results of the probabilistic 
sensitivity analysis showed that the probability of omalizumab being cost effec-
tive was 58% and 84%, at a willingness to pay threshold of € 30,000 and € 40,000, 
respectively. cOnclusiOns: Omalizumab appears to be a cost-effective treatment 
option for adult patients with severe allergic asthma compared with ST in Greece, 
confirmed by both trial and real-world data.
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Objectives: To assess the cost-effectiveness (CE) of indacaterol/glycopyrronium 
(QVA149; 85µg/43µg) as a maintenance bronchodilator treatment of adult patients 
with Chronic Obstructive Pulmonary Disease (COPD) versus salmeterol/flutica-
sone (SFC; 50µg/500µg). MethOds: A CE model of micro-simulation over a 3-, 5-, 
10-year and lifetime horizon was developed from the perspective of the Spanish 
National Healthcare System. Patients progress through subsequent COPD stages 
based on their baseline characteristics and considering the natural decline of 
Forced Expiratory Volume in 1 second (FEV1) and exacerbation rate. In the model 
this is counteracted by treatment-associated FEV1 improvement from baseline and 
exacerbation rate reduction associated to each treatment vs. placebo, which were 
obtained by direct and indirect comparison of primary data from TORCH (SFC vs. 
placebo), SHINE (QVA149 vs. placebo) and ILLUMINATE (QVA149 vs SFC) clinical 
trials. The considered outcomes were life years (LY) gained and quality-adjusted 
life years (QALYs). Cost estimates (Euros 2014) include drugs, disease management 
and mild/severe exacerbation expenditures from Spanish health care cost data-
bases and publications with a discount rate of 3% for costs and effects. Results: 
QVA149 has shown to be less costly and more effective than the fixed combination 
of SFC with respect to both LY and QALYs gained. The cost per patient treated with 
QVA149 over a 3-, 5-, 10-year and lifetime period was estimated to be € 108, € 182, 
€ 305, and € 467 lower than with SFC, which resulted from avoiding exacerbation 
costs and decreasing maintenance cost in relation to slowing COPD progression. 
Therefore, QVA149 was estimated to be dominant over SFC with respect to both 
cost-effectiveness and cost-utility. cOnclusiOns: Due to its higher effectiveness 
in improving FEV1 and reducing COPD exacerbations, QVA149 has shown to be 
more cost-effective than SFC.
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Objectives: To determine the relative impact of treatment with Oralair®, Grazax®, 
Pangramin®, Pollinex Quattro®, and symptomatic drug treatment (SDT) on clinical 
effects and health care costs in patients with grass pollen-induced allergic rhinitis 
(AR) in Spain. MethOds: The effects of three years of drug treatment on quality-
adjusted life years (QALYs) and costs were assessed using a Markov model with 
a nine-year time horizon. Symptom score data were extracted, and the relative 
efficacy on QALYs was assessed through a network meta-analysis (i. e. indirect 
comparison) of 3-year, placebo-controlled, clinical trial data. Patient symptom scores 
were translated into the impact on quality of life by means of published sources. 
Costs associated with drug treatment and other health care resources were calcu-
lated. The incremental costs and QALYs gained were generated accordingly. The 
uncertainty around the model outcomes was determined by means of sensitiv-
ity analyses. Results: The base case analysis over 9 years estimated incremental 
QALYs of 0.005 (95%CI: -0.024; 0.038), 0.016 (95%CI: -0.034; 0.063), 0.059 (95%CI: 0.024; 
0.107), and 0.143 (95%CI: 0.102; 0.195) when Oralair® was compared to Grazax®, 
Pangramin®, Pollinex Quattro® and SDT, respectively. Corresponding incremental 
costs were -€ 1,063 (95%CI: -€ 1,306; -€ 779), € 109 (95%CI: €206; € 428), € 572 (95%CI: € 321; 
€ 864), and € 1,360 (95%CI: € 1,110; € 1,649). Hence, Oralair® was predicted as domi-
nant relative to Grazax®, while ICERs of € 6,931/QALY, € 9,703/QALY, and € 9,517/QALY 
were estimated relative to Pangramin®, Pollinex Quattro®, and SDT, respectively. 
Apart from drug costs, the sensitivity analyses suggest that results were mostly 
driven by drug-specific symptom score values, duration of the pollen season, and 
inputs for immunotherapy discontinuation. At a willingness-to-pay threshold of 
€ 20,000, the probability of Oralair® being the most cost-effective treatment option 
is 65%. cOnclusiOns: Oralair® is cost-effective relative to Grazax®, Pangramin®, 
